{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:04:47Z","timestamp":1783897487697,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Concurrent bacteremia in febrile neutropenia is associated with increased mortality, but there is limited data regarding the impact of neutropenia severity on patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted among adults (age\u2009&gt;\u200918) with hematologic or solid malignancies who developed neutropenic bacteremia and received definitive cefepime treatment for &gt;\u200948\u00a0h. Those who had severe neutropenia (absolute neutrophil count [ANC] 100\u2013500 cells\/\u00b5L) or profound neutropenia (ANC\u2009&lt;\u2009100 cells\/\u00b5L) were included in the analysis. Cox proportional hazards model was used to determine the independent predictors of 30-day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 200 bacteremias with an overall mortality rate of 13.5%. There was no difference in mortality between the profound and severe neutropenia groups (11.3% vs. 20.0%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.121). After adjusting for the confounding factors, profound neutropenia was not associated with 30-day mortality (adjusted hazard ratio [aHR] 0.73; 95% CI, 0.31\u20131.75;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.484). Major predictors of 30-day mortality were pneumonia as the infection source (aHR 3.81; 95% CI, 1.23\u201311.78), higher Pitt bacteremia scores (aHR 1.26 per point), and increased Charlson comorbidity index (aHR 1.27 per point). Notably, patients with solid tumors had significantly higher 14-day mortality compared to those with hematologic malignancies (16.9% vs. 7.0%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.029). A relatively longer length of stay was observed in the profound neutropenia group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.096).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with neutropenic bacteremia treated with appropriate antibiotics, the severity of neutropenia is not associated with 30-day mortality. Our findings suggest that the potential risk associated with profound neutropenia may be mitigated by the appropriate antimicrobial therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13574-2","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:56:23Z","timestamp":1778903783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does the severity of neutropenia affect mortality in bacteremic cancer patients?"],"prefix":"10.1186","volume":"26","author":[{"given":"Peng-Hao","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shian-Sen","family":"Shie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Ling","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jiun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Fu","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Tai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"issue":"16","key":"13574_CR1","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038\u201351.","journal-title":"J Clin Oncol"},{"issue":"7","key":"13574_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1093\/annonc\/mdr520","volume":"23","author":"S Schelenz","year":"2012","unstructured":"Schelenz S, Giles D, Abdallah S. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional uk cancer centre. Ann Oncol. 2012;23(7):1889\u201393.","journal-title":"Ann Oncol"},{"issue":"3","key":"13574_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/21505594.2016.1156821","volume":"7","author":"G Gustinetti","year":"2016","unstructured":"Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: A practical update. Virulence. 2016;7(3):280\u201397.","journal-title":"Virulence"},{"issue":"Suppl 1","key":"13574_CR4","first-page":"0924","volume":"30","author":"J Klastersky","year":"2007","unstructured":"Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(Suppl 1):0924\u20138579.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"13574_CR5","doi-asserted-by":"publisher","first-page":"878","DOI":"10.15537\/smj.2018.9.22824","volume":"39","author":"S Calik","year":"2018","unstructured":"Calik S, Ari A, Bilgir O, Cetintepe T, Yis R, Sonmez U, et al. The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies. Saudi Med J. 2018;39(9):878\u201385.","journal-title":"Saudi Med J"},{"issue":"11","key":"13574_CR6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1159\/000506109","volume":"43","author":"J Moreira-Pinto","year":"2020","unstructured":"Moreira-Pinto J, Leao I, Palmela C, Branco F, Godinho J, Simoes P, et al. Febrile neutropenia in patients with solid tumors undergoing intravenous chemotherapy. Oncol Res Treat. 2020;43(11):605\u201312.","journal-title":"Oncol Res Treat"},{"issue":"7","key":"13574_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/INF.0000000000002641","volume":"39","author":"M Alali","year":"2020","unstructured":"Alali M, David MZ, Danziger-Isakov LA, Bartlett AH, Petty LA, Schwartz T, et al. Association between depth of neutropenia and clinical outcomes in febrile pediatric cancer and\/or patients undergoing hematopoietic stem-cell transplantation. Pediatr Infect Dis J. 2020;39(7):628\u201333.","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"13574_CR8","doi-asserted-by":"publisher","first-page":"102538","DOI":"10.1016\/j.jiac.2024.10.006","volume":"31","author":"AF Florez Riano","year":"2025","unstructured":"Florez Riano AF, Rojas Castro OJ, Ospina S, Ramirez-Sanchez IC. Association between inappropriate empirical antimicrobial therapy and mortality in gram-negative bloodstream infections in patients with febrile neutropenia and hematological malignancy. J Infect Chemother. 2025;31(2):102538.","journal-title":"J Infect Chemother"},{"issue":"12","key":"13574_CR9","doi-asserted-by":"publisher","first-page":"e51612","DOI":"10.1371\/journal.pone.0051612","volume":"7","author":"M Tumbarello","year":"2012","unstructured":"Tumbarello M, Trecarichi EM, Caira M, Candoni A, Pastore D, Cattaneo C, et al. Derivation and validation of a scoring system to identify patients with bacteremia and hematological malignancies at higher risk for mortality. PLoS ONE. 2012;7(12):e51612.","journal-title":"PLoS ONE"},{"issue":"9","key":"13574_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.6004\/jnccn.2024.0056","volume":"22","author":"LR Baden","year":"2024","unstructured":"Baden LR, Swaminathan S, Almyroudis NG, Angarone M, Baluch A, Barros N, et al. Prevention and treatment of cancer-related infections, version 3.2024, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(9):617\u201344.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"13574_CR11","doi-asserted-by":"publisher","first-page":"106571","DOI":"10.1016\/j.jinf.2025.106571","volume":"91","author":"F Baccelli","year":"2025","unstructured":"Baccelli F, Aguilar-Guisado, CG Vidal M, Mikulska M, Vanbiervliet Y, Blijlevens N, et al. Epidemiology of resistant bacterial infections in patients with hematological malignancies or undergoing hematopoietic cell transplantation in europe: A systematic review by the european conference on infections in leukemia (ecil). J Infect. 2025;91(3):106571.","journal-title":"J Infect"},{"key":"13574_CR12","doi-asserted-by":"crossref","unstructured":"Li CH, Chang PH, Huang CT, Ng CJ. Comparative analysis of the effectiveness of generic and brand-name cefepime: a multicenter retrospective cohort study. Life (Basel) 2025;15(2).","DOI":"10.3390\/life15020164"},{"issue":"11","key":"13574_CR13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245\u201351.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"13574_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S0002-9343(89)80611-4","volume":"87","author":"M Hilf","year":"1989","unstructured":"Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients. Am J Med. 1989;87(5):540\u20136.","journal-title":"Am J Med"},{"issue":"3","key":"13574_CR15","doi-asserted-by":"publisher","first-page":"ofab624","DOI":"10.1093\/ofid\/ofab624","volume":"9","author":"A Verlinden","year":"2022","unstructured":"Verlinden A, Jansens H, Goossens H, Anguille S, Berneman ZN, Schroyens WA, et al. Safety and efficacy of antibiotic de-escalation and discontinuation in high-risk hematological patients with febrile neutropenia: A single-center experience. Open Forum Infect Dis. 2022;9(3):ofab624.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"13574_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13756-022-01084-0","volume":"11","author":"A Contejean","year":"2022","unstructured":"Contejean A, Abbara S, Chentouh R, Alviset S, Grignano E, Gastli N, et al. Antimicrobial stewardship in high-risk febrile neutropenia patients. Antimicrob Resist Infect Control. 2022;11(1):52.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"9","key":"13574_CR17","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1093\/jac\/dkac190","volume":"77","author":"R Paret","year":"2022","unstructured":"Paret R, Le Bourgeois A, Guillerm G, Tessoulin B, Rezig S, Gastinne T, et al. Safety and risk of febrile recurrence after early antibiotic discontinuation in high-risk neutropenic patients with haematological malignancies: A multicentre observational study. J Antimicrob Chemother. 2022;77(9):2546\u201356.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"13574_CR18","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258\u201366.","journal-title":"Cancer"},{"issue":"2","key":"13574_CR19","first-page":"303","volume":"9","author":"A Lal","year":"2008","unstructured":"Lal A, Bhurgri Y, Rizvi N, Virwani M, Memon RU, Saeed W, et al. Factors influencing in-hospital length of stay and mortality in cancer patients suffering from febrile neutropenia. Asian Pac J Cancer Prev. 2008;9(2):303\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"13574_CR20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/MCP.0000000000000156","volume":"21","author":"SE Evans","year":"2015","unstructured":"Evans SE, Ost DE. Pneumonia in the neutropenic cancer patient. Curr Opin Pulm Med. 2015;21(3):260\u201371.","journal-title":"Curr Opin Pulm Med"},{"issue":"5","key":"13574_CR21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.cmi.2024.01.005","volume":"30","author":"L Biyun","year":"2024","unstructured":"Biyun L, Yahui H, Yuanfang L, Xifeng G, Dao W. Risk factors for invasive fungal infections after haematopoietic stem cell transplantation: A systematic review and meta-analysis. Clin Microbiol Infect. 2024;30(5):601\u201310.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"13574_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/ajh.26177","volume":"96","author":"K Obrova","year":"2021","unstructured":"Obrova K, Grumaz S, Remely M, Czurda S, Krickl I, Herndlhofer S, et al. Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. Am J Hematol. 2021;96(6):719\u201326.","journal-title":"Am J Hematol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13574-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13574-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13574-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T22:28:20Z","timestamp":1783895300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13574-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13574"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13574-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Review Board (IRB) of the Chang Gung Memorial Hospital, Linkou Branch (IRB No. 202400050B0), and was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective design and the use of de-identified data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the preparation of this work, the authors used Grammarly to help correct grammatical errors and improve the clarity. The authors have thoroughly reviewed the manuscript and take full responsibility for the content of the published article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the manuscript preparation process"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1282"}}